TABLE 1.

Challenges in Diagnosis, Prognostication, and Therapeutics Development for MAFLD

Process	Challenges
Screening/Diagnosis	Imperfect/evolving nomenclature
	Disease heterogeneity
	Coexistance of alternative chronic liver diseases
	Lack of early and sensitive testing for at‐risk individuals
	Cost and availability of testing modalities
Staging/surveillance	Lack of accurate modalities to detect steatohepatitis and early/intermediate fibrosis
	Inefficient surveillance tools to monitor therapeutic response
Treatment	Limited pharmacotherapy
	Lack of tools to predict therapeutic response
	Clinical trial enrollment and retention limitations
Prognostication	Cardiovascular and oncologic comorbidities
	Long latency period prior to the development of liver‐related outcomes
	Variability in disease progression